Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thoracic Radiotherapy plus Durvalumab in Elderly/Frail Unfit Stage III NSCLC
2024-513948-28-00Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Institut für Klinische Krebsforschung. Started Aug 2024; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-513948-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513948-28-00.